VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer - Wikidata - awgldk - TriplyDB

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

http://www.wikidata.org/entity/Q35112894

about

Tumor angiogenesis: pericytes and maturation are not to be ignored Mouse models for studying angiogenesis and lymphangiogenesis in cancer Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Novel therapies for metastatic castrate-resistant prostate cancer.A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling The role played by perivascular cells in kidney interstitial injury MET and VEGF: synergistic targets in castration-resistant prostate cancer Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6 Collagen VI ablation retards brain tumor progression due to deficits in assembly of the vascular basal lamina.Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.Targeting the HGF/c-MET pathway in hepatocellular carcinoma.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer.Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.VEGFR and type-V RTK activation and signaling Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells The VEGF signaling pathway in cancer: the road ahead.

P2860

Q21296683-FF8E0AD2-645F-48BC-9550-EFF91D7138CA Q27003898-BEB01C57-3B60-4476-8A56-F3D2B633C9A5 Q27004077-CAD3112A-DF36-4013-AF50-29538616583B Q28074834-320A56B5-595E-492F-8FD5-DF00985CEC89 Q28487568-09C61FA8-4DF4-4870-9528-600B835B5B12 Q28487748-1F8E7E06-9C2A-4846-A147-93AEE9AA93DF Q30399006-CD1BAB4B-7DD9-4BEA-B2D1-488CD823BD90 Q30759342-07184336-0C9F-4D93-82A7-07204DC601D7 Q33410375-91830FB0-6E3C-4990-A164-A4C0720BBB41 Q33434042-F0D8FC7A-2D68-41AF-B71A-BDD5CAAA0A3F Q33721142-75D1CFFF-8A31-4F1C-8351-2D064BA0EA28 Q33946929-B89E8231-E72F-45B8-8718-1317353E9D60 Q34249263-BFB9FA44-9686-46AC-B217-EF7787F64D17 Q34326409-5D78BB46-F7D4-4778-A3D9-00DCE8C5A591 Q34537725-9B391A7C-D55E-46CF-AB11-DC919D2F2571 Q34541663-AD08B3F4-4598-4A16-A7FF-B8A4DEBE46ED Q34665377-9157A594-037E-466E-B868-40DF14536A4A Q34774912-A7543877-7AD6-45E2-A4AE-6D6CD8F1E85D Q35036800-92C6636F-94E9-4703-A584-FF7ABEC32FE1 Q35530317-116916C5-9CC4-4160-B3D5-42EECEFE05C5 Q35575488-10A38AE0-30EF-474E-914A-4A42D61203C8 Q35625440-494393C1-5E67-48EF-8C95-A14C1AE8833C Q35951999-53545225-41A9-42F7-9889-7DAF2CF646CE Q35967197-412EE047-4B2E-4A09-A65B-010AF591FE6D Q36020888-10968EF6-CFF5-4CE9-B1E4-7069204B3EC7 Q36084097-1B5707B5-8664-4A00-A188-F026D6232F85 Q36093497-A039B4CB-0083-45C6-8A80-6BA42C0968C5 Q36428702-83976478-DE43-4E0B-8E5F-739614F45D03 Q36436763-639ACC26-69F7-42C1-8A49-6AAA0679829E Q36505652-72629F11-9351-49DB-A41E-E2045ED1AA1D Q36520616-8E4BCE66-479B-4333-8294-EA23C3892BAA Q36703854-EFAE539C-37D0-4B43-B8F1-00ACCFCDE6F4 Q36828050-30CA0043-F6FB-436A-A862-47D1912E6C2D Q36867324-C0374BC1-CAE8-47AF-BFA0-67C647744C07 Q36907124-C10F6992-24C9-4441-96C3-A3400613DDB4 Q36941168-A7ABAD1B-3AF5-485D-B211-5987FD54309B Q37141599-53506694-C326-4113-A605-E6BC670780FF Q37197494-71E68DD1-B582-4033-9E78-450E97628B13 Q37228831-341D7061-D6BA-4A36-A5C2-3B063406DCFD Q37354128-261F1CC1-F146-4E23-ABD9-45B06765C6DB

P2860

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

http://www.wikidata.org/entity/Q35112894

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@ast

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@en

type

label

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@ast

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@en

prefLabel

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@ast

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@en

P1433

Q35112894-47E0B820-F751-47E1-B2CF-D7109C7C2C47

P1476

Q35112894-14D31C95-0D6E-4A5E-8BFE-70B761B6750B

P2093

Q35112894-27F0B25E-B808-4EED-9614-43802DA55179

Q35112894-7123D1CC-0801-48BC-9588-A1ED1D0162FE

Q35112894-7CFAA1C1-0470-4FDE-9E3F-16CC0E5945A6

Q35112894-BA1F5FEA-0B71-4517-A452-4B514E4B3019

Q35112894-C1D15536-0467-40E1-8DD5-1D588567CB65

Q35112894-C7212855-A2D0-4CEA-AAAD-62EC0D1DD51E

Q35112894-DE181B35-68F8-4C45-A54B-E9FB1C5B5AA8

Q35112894-FE667A8B-DED1-4CE6-A689-C66492DC512A

P2860

Q35112894-0A3B443B-2E59-4D0C-90BA-4E4FB6F79573

Q35112894-0D072C6F-4B33-46B3-B070-9D09B2508850

Q35112894-102F7932-CDC4-4EDD-9EBF-BE1A0F4A1C09

Q35112894-15ADEC03-3DD1-4101-B3EE-6F07FACCA572

Q35112894-16BD5F18-5F10-4D6A-9E4B-A4BA746FB5FC

Q35112894-19864025-866B-4753-A6A7-243A505F7BBF

Q35112894-1EE5E5BC-810E-489D-9A8D-92FE5A92C88E

Q35112894-20AAB9AA-AB8A-44A3-ADC3-A56D83B2E37E

Q35112894-35F5EC84-E572-4FFE-8B80-C1C10635AB86

Q35112894-3C8B30C8-2B7F-4B97-9445-511FA4B01409

P304

Q35112894-8726EB91-C330-4CBA-A29F-5042E58E8378

P31

Q35112894-89AFCBC7-300F-4DC9-B94A-CBCAC6BDE40B

P356

Q35112894-EF21E3A3-1905-4CDE-AE69-7D8884FC9FDF

P407

Q35112894-63393D6A-C1F4-423D-BDAD-BCA67E7BD082

P433

Q35112894-35B80A43-427E-4FC5-B64F-92C778E576A4

P478

Q35112894-D520A179-1EEB-4787-96D0-3EFC1E807E03

P577

Q35112894-32AA15B8-B34D-4D1D-9DD6-9C1FE75B67EF

P698

Q35112894-39DA3C43-86FB-4E5A-AAF6-F89FCAC75A16

P921

Q35112894-4A3CEB20-3298-49D2-A355-C8AE5CC485E2

P932

Q35112894-4F001456-CA52-46E2-AFA0-AA22CED5C40E

P356

0008-5472.CAN-10-2527

P1433

Cancer Research

P1476

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

@en

P2093

Barbara Sennino

http://www.w3.org/2001/XMLSchema#string

Beverly Falcón

http://www.w3.org/2001/XMLSchema#string

Casey W Williamson

http://www.w3.org/2001/XMLSchema#string

Dana T Aftab

http://www.w3.org/2001/XMLSchema#string

Donald M McDonald

http://www.w3.org/2001/XMLSchema#string

Hiroya Hashizume

http://www.w3.org/2001/XMLSchema#string

Li-Chin Yao

http://www.w3.org/2001/XMLSchema#string

Weon-Kyoo You

http://www.w3.org/2001/XMLSchema#string

P2860

Cutting off cancer's supply lines

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Met, metastasis, motility and more

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

P304

4758-4768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-2527

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21613405

http://www.w3.org/2001/XMLSchema#string

P921

P932

3138890

http://www.w3.org/2001/XMLSchema#string